INTENSITY THERAPEUTICS, INC.

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company specializing in immunity against cancer. The company develops drugs based on Cisplatin, which has already demonstrated its effectiveness in preventing several types of cancer. Additionally, the company has several drugs in Phase 2 and 3 clinical trials, which presents good potential for further growth in the company's stocks.